CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Combination Treatment with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03153085
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:04.007008+00:00
Published At: 2024-12-09T00:00:00+00:00
Record Updated At: 2024-12-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma Stage III", "Melanoma Stage IV"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-12-09"
protocolSection.identificationModule.nctId: "NCT03153085"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Combination Treatment with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.